Status:
COMPLETED
Amyloid Plaque and Tangle Imaging in Aging and Dementia
Lead Sponsor:
University of California, Los Angeles
Collaborating Sponsors:
National Institute on Aging (NIA)
Conditions:
Memory Disorders
Alzheimer's Disease
Eligibility:
All Genders
30+ years
Brief Summary
Amyloid senile plaques (SPs) and neurofibrillary tangles (NFTs) are neuropathological hallmarks of Alzheimer's disease (AD) that also accumulate in key brain regions in association with normal aging. ...
Detailed Description
A total of 165 volunteers will be recruited for this 2-year study. Participants will receive a baseline clinical and imaging evaluation and one follow-up evaluation two years later. These evaluations ...
Eligibility Criteria
Inclusion
- Agreement to participate in a clinical and brain imaging study
- Age 30 years or older
- No significant cerebrovascular disease - modified Ischemic Score of ≤ 4
- For volunteers with MCI or dementia, there must be a family member or potential caregiver available
- Adequate visual and auditory acuity to allow neuropsychological testing
- Screening laboratory tests and ECG without significant abnormalities that might interfere with the study.
Exclusion
- Evidence of neurologic or other physical illness that could produce cognitive deterioration; in addition to a physical and neurological examination, volunteers will be screened for Parkinson's disease
- History of myocardial infarction within the previous year or unstable cardiac disease
- Uncontrolled hypertension (systolic BP\>170 or diastolic BP\>100), history of significant liver disease, clinically significant pulmonary disease, diabetes, or cancer
- Major psychiatric disorders, such as bipolar disorder or schizophrenia
- Because medications can affect cognitive functioning, volunteers needing medicines that could influence psychometric test results will be excluded; use of any of the following drugs will also exclude volunteers: centrally active beta-blockers, narcotics, clonidine, anti-Parkinsonian medications, benzodiazepines, systemic corticosteroids, and medications with significant cholinergic or anticholinergic effects, anti-convulsants, or warfarin
- Current diagnosis or history of alcoholism or drug dependence
- Evidence of untreated depression as determined by a HAM-D (Hamilton, 1960) score of ≥ 12 (17-item version) or untreated anxiety by a score of ≥ 8 on the Hamilton Anxiety Scale (HAM-A; Hamilton, 1959)
- Use of any investigational drugs within the previous month or longer, depending on drug half-life
- Contraindication for MRI scan (e.g., metal in body, claustrophobia)
Key Trial Info
Start Date :
September 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2010
Estimated Enrollment :
170 Patients enrolled
Trial Details
Trial ID
NCT00355498
Start Date
September 1 2005
End Date
May 1 2010
Last Update
May 6 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jane & Terry Semel Institute for Neuroscience & Human Behavior
Los Angeles, California, United States, 90024